DE602006019231D1 - Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid - Google Patents

Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid

Info

Publication number: DE602006019231D1
Authority: DE; Germany
Prior art keywords: methylpyridin; ethoxyethyl; ethyl; methylaminoü; düpyrimidin
Prior art date: 2005-05-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602006019231T

Other languages

English (en)

Inventor

David Andrew Entwistle

Peter Vallance Marshall

Stefan Colin John Taylor

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2006-05-03

Publication date

2011-02-10

2006-05-03 Application filed by Pfizer Inc filed Critical Pfizer Inc

2011-02-10 Publication of DE602006019231D1 publication Critical patent/DE602006019231D1/de

Status Active legal-status Critical Current

2026-05-04 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)

DE602006019231T 2005-05-12 2006-05-03 Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid Active DE602006019231D1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US68044505P	2005-05-12	2005-05-12
US68171105P	2005-05-17	2005-05-17
PCT/IB2006/001233 WO2006120552A2 (en)	2005-05-12	2006-05-03	ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE

Publications (1)

Publication Number	Publication Date
DE602006019231D1 true DE602006019231D1 (en)	2011-02-10

Family

ID=37106941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602006019231T Active DE602006019231D1 (en)	2005-05-12	2006-05-03	Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid

Country Status (24)

Country	Link
US (3)	US8227475B2 (de)
EP (1)	EP1881985B1 (de)
JP (2)	JP4271695B2 (de)
KR (1)	KR100939890B1 (de)
AT (1)	ATE493413T1 (de)
AU (1)	AU2006245416B2 (de)
BR (1)	BRPI0609225A2 (de)
CA (1)	CA2608018C (de)
CR (1)	CR9505A (de)
CY (1)	CY1111171T1 (de)
DE (1)	DE602006019231D1 (de)
DK (1)	DK1881985T3 (de)
EA (1)	EA012577B1 (de)
HK (1)	HK1116485A1 (de)
IL (1)	IL186693A (de)
MA (1)	MA29447B1 (de)
MX (1)	MX2007013215A (de)
NO (1)	NO20075258L (de)
NZ (1)	NZ564187A (de)
PL (1)	PL1881985T3 (de)
PT (1)	PT1881985E (de)
TN (1)	TNSN07414A1 (de)
TW (1)	TWI380986B (de)
WO (1)	WO2006120552A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7676953B2 (en)	2006-12-29	2010-03-16	Signature Control Systems, Inc.	Calibration and metering methods for wood kiln moisture measurement
WO2009050554A2 (en) *	2007-10-19	2009-04-23	Pfizer Inc.	Treatment of central nervous system disorders
WO2012048330A2 (en) *	2010-10-08	2012-04-12	The Mclean Hospital Corporation	Treatment of motor neuron disease
JP5767393B2 (ja)	2011-03-31	2015-08-19	ファイザー・インク	新規二環式ピリジノン
SG194549A1 (en)	2011-04-21	2013-12-30	Origenis Gmbh	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
CN102952138B (zh) *	2011-08-17	2016-07-06	上海特化医药科技有限公司	一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
ES2605565T3 (es)	2011-08-31	2017-03-15	Pfizer Inc	Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
US9260455B2 (en)	2012-09-20	2016-02-16	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
WO2014060112A1 (en)	2012-10-19	2014-04-24	Origenis Gmbh	Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
CA2888160A1 (en)	2012-10-23	2014-05-01	Pfizer Inc.	Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy
JP2016502978A (ja)	2012-12-11	2016-02-01	ファイザー・インク	ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014097038A1 (en)	2012-12-19	2014-06-26	Pfizer Inc.	CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (de)	2013-02-13	2017-08-09	Pfizer Inc	Heteroarylsubstituierte hexahydropyrano[3,4-d][1,3]thiazin-2-amin-verbindungen
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MX2015010714A (es)	2013-02-19	2016-06-14	Pfizer	Compuestos de azabencimidazol.
ES2742078T3 (es)	2013-10-04	2020-02-13	Pfizer	Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CR20160454A (es)	2014-04-01	2016-12-06	Pfizer	CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
PE20170327A1 (es)	2014-04-10	2017-04-21	Pfizer	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
US10131669B2 (en)	2014-07-24	2018-11-20	Pfizer Inc.	Pyrazolopyrimidine compounds
EA031201B1 (ru)	2014-08-06	2018-11-30	Пфайзер Инк.	Соединения имидазопиридазина
EA033423B1 (ru)	2015-02-03	2019-10-31	Pfizer	Циклопропанбензофуранилпиридопиразиндионы
CN107787322B (zh)	2015-06-17	2023-07-07	辉瑞大药厂	三环化合物以及它们作为磷酸二酯酶抑制剂的用途
JP2018534251A (ja)	2015-09-24	2018-11-22	ファイザー・インク	Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531923A (ja)	2015-09-24	2018-11-01	ファイザー・インク	Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (de)	2015-09-24	2018-08-01	Pfizer Inc	Tetrahydropyrano[3,4-d][1,3]oxazin-derivate und deren verwendung als bace-inhibitoren
US10323042B2 (en)	2016-02-23	2019-06-18	Pfizer Inc.	6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
ES2878160T3 (es)	2016-07-01	2021-11-18	Pfizer	Derivados de 5,7-dihidro-pirrolo-piridina para el tratamiento de enfermedades neurológicas y neurodegenerativas
PT3642202T (pt)	2017-06-22	2023-02-02	Pfizer	Derivados de dihidro-pirrolo-piridina
FI3768669T3 (fi)	2018-03-23	2023-04-26	Pfizer	Piperatsiiniatsaspirojohdannaisia
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
EA004315B1 (ru)	1997-04-25	2004-02-26	Пфайзер Инк.	Новые сульфонилбензойные кислоты и способ получения 4-бензамидопиразоло-5-карбоксамидов с их использованием
ATE213246T1 (de)	1997-11-12	2002-02-15		2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
HUP0102543A3 (en)	1998-04-20	2002-01-28	Pfizer	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
WO2000024745A1 (en)	1998-10-23	2000-05-04	Pfizer Limited	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
DE19942474A1 (de)	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
TR200200954T2 (tr)	1999-10-11	2002-09-23	Pfizer Inc.	Fosfodiesteraz inhibitörleri olarak 5-(2-ikame edilmiş-5-heterosiklilsülfonilpirid-3-il)- dihidropirazolo[4,3- D]pirimidin-7-onlar.
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
DE10031584A1 (de)	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
HUP0302982A3 (en)	2000-07-28	2005-01-28	Pfizer	Crystalline therapeutic agent
DK1348707T3 (da) *	2002-03-28	2010-12-13	Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro	Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
RS20050810A (en)	2003-04-29	2007-08-03	Pfizer Inc.,	5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
GB0327323D0 (en)	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
US7572799B2 (en) *	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1742950B1 (de)	2004-04-07	2008-12-17	Pfizer Limited	Pyrazolo[4,3-d]pyrimidine
EP1809632A2 (de)	2004-10-28	2007-07-25	Pharmacia & Upjohn Company LLC	Als pde-5-inhibitoren geeignetepyrazolo[4,3-d]pyrimidinderivate

2006
- 2006-05-03 DE DE602006019231T patent/DE602006019231D1/de active Active
- 2006-05-03 MX MX2007013215A patent/MX2007013215A/es active IP Right Grant
- 2006-05-03 US US11/913,091 patent/US8227475B2/en not_active Expired - Fee Related
- 2006-05-03 PT PT06744689T patent/PT1881985E/pt unknown
- 2006-05-03 BR BRPI0609225-0A patent/BRPI0609225A2/pt not_active IP Right Cessation
- 2006-05-03 DK DK06744689.8T patent/DK1881985T3/da active
- 2006-05-03 WO PCT/IB2006/001233 patent/WO2006120552A2/en not_active Application Discontinuation
- 2006-05-03 AT AT06744689T patent/ATE493413T1/de active
- 2006-05-03 PL PL06744689T patent/PL1881985T3/pl unknown
- 2006-05-03 CA CA2608018A patent/CA2608018C/en not_active Expired - Fee Related
- 2006-05-03 EP EP06744689A patent/EP1881985B1/de active Active
- 2006-05-03 NZ NZ564187A patent/NZ564187A/en not_active IP Right Cessation
- 2006-05-03 AU AU2006245416A patent/AU2006245416B2/en not_active Ceased
- 2006-05-03 EA EA200702217A patent/EA012577B1/ru not_active IP Right Cessation
- 2006-05-03 KR KR1020077026098A patent/KR100939890B1/ko not_active IP Right Cessation
- 2006-05-11 TW TW095116704A patent/TWI380986B/zh not_active IP Right Cessation
- 2006-05-11 JP JP2006132110A patent/JP4271695B2/ja not_active Expired - Fee Related
2007
- 2007-10-12 NO NO20075258A patent/NO20075258L/no not_active Application Discontinuation
- 2007-10-16 IL IL186693A patent/IL186693A/en not_active IP Right Cessation
- 2007-11-09 CR CR9505A patent/CR9505A/es unknown
- 2007-11-09 TN TNP2007000414A patent/TNSN07414A1/fr unknown
- 2007-11-12 MA MA30362A patent/MA29447B1/fr unknown
2008
- 2008-06-20 HK HK08106870.4A patent/HK1116485A1/xx not_active IP Right Cessation
2009
- 2009-01-07 JP JP2009001627A patent/JP4996631B2/ja not_active Expired - Fee Related
2011
- 2011-02-08 CY CY20111100142T patent/CY1111171T1/el unknown
2012
- 2012-04-27 US US13/457,969 patent/US8796288B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,886 patent/US8796287B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8796288B2 (en)	2014-08-05
CA2608018A1 (en)	2006-11-16
JP4996631B2 (ja)	2012-08-08
TNSN07414A1 (fr)	2009-03-17
US20120208830A1 (en)	2012-08-16
MA29447B1 (fr)	2008-05-02
CR9505A (es)	2008-01-02
KR100939890B1 (ko)	2010-01-29
NO20075258L (no)	2007-11-15
JP4271695B2 (ja)	2009-06-03
JP2009137987A (ja)	2009-06-25
MX2007013215A (es)	2007-12-12
EA200702217A1 (ru)	2008-04-28
NZ564187A (en)	2010-03-26
WO2006120552A2 (en)	2006-11-16
CY1111171T1 (el)	2015-06-11
ATE493413T1 (de)	2011-01-15
TW200716641A (en)	2007-05-01
PL1881985T3 (pl)	2011-05-31
BRPI0609225A2 (pt)	2010-03-09
EA012577B1 (ru)	2009-10-30
PT1881985E (pt)	2011-02-01
US8796287B2 (en)	2014-08-05
IL186693A (en)	2012-07-31
TWI380986B (zh)	2013-01-01
IL186693A0 (en)	2008-02-09
AU2006245416A1 (en)	2006-11-16
US20120214827A1 (en)	2012-08-23
AU2006245416B2 (en)	2012-02-23
WO2006120552A3 (en)	2007-01-18
US8227475B2 (en)	2012-07-24
DK1881985T3 (da)	2011-02-14
EP1881985B1 (de)	2010-12-29
CA2608018C (en)	2010-07-13
KR20080004593A (ko)	2008-01-09
JP2006316058A (ja)	2006-11-24
HK1116485A1 (de)	2008-12-24
US20080194591A1 (en)	2008-08-14
EP1881985A2 (de)	2008-01-30

Publication	Publication Date	Title
DE602006019231D1 (en)	2011-02-10	Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid
WO2007067506A3 (en)	2007-08-16	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2006068826A3 (en)	2006-10-05	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2006116148A3 (en)	2008-09-12	(7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2003095455A3 (en)	2003-12-24	Substituted pyrazolopyrimidines
WO2004074244A3 (en)	2004-11-11	Pyrimidine compounds
TNSN07323A1 (en)	2008-12-31	Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors
WO2007068934A3 (en)	2008-02-21	Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
HK1096673A1 (en)	2007-06-08	Compositions useful as inhibitors of protein kinases
IL188475A0 (en)	2008-04-13	Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors
ZA200702645B (en)	2008-08-27	Diaminotriazole compounds useful as protein kinase inhibitors
WO2007084424A3 (en)	2007-10-04	Treatment of substance abuse
UA83091C2 (en)	2008-06-10	Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
WO2007120333A3 (en)	2008-01-10	Tetracyclic kinase inhibitors
UA86591C2 (ru)	2009-05-12	Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
WO2007056625A3 (en)	2008-09-12	Thienopyridine b-raf kinase inhibitors
WO2004096233A3 (en)	2005-06-16	Nucleoside phosphonate conjugates
TW200738723A (en)	2007-10-16	1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof
WO2006124865A3 (en)	2007-01-11	Biaryls derivatives useful as modulators of ion channels
GR1004358B (el)	2003-10-07	Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
WO2004098577A3 (en)	2004-12-09	Dosage form containing (s)-pantoprazole as active ingredient
WO2006044753A3 (en)	2006-08-17	Chemical compounds
WO2007025031A3 (en)	2007-06-14	Prodrugs of indanone and tetralone compounds
WO2005077951A3 (en)	2006-03-02	7h-pyrrolopyrimidine derivatives
AP2007004219A0 (en)	2007-10-31	Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-YL-amino)-1H-pyrazolo[4,3-D] pyrimidine-3-carbonyl]methanesulfonamide